TransMedics Group, Inc.(TMDX) Stock Research - Grey Stern Research

TransMedics Group, Inc. (TMDX) Stock Analysis

$60.44 (-3.36%)

TMDX Financial Performance


Use the table below to view TransMedics Group, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $60.44 -
52 Week Low $58.27 -
52 Week High $177.37 -
Market Cap $2.0 Billion 7/15
Gross Margin 56% 14/15
Profit Margin 4% 7/15
EBITDA margin 8% 5/15
Q3 - 2024 Revenue $108.8 Million 9/15
Q3 - 2024 Earnings $4.2 Million 7/15
Q3 - 2024 Free Cash Flow -$41.3 Million 15/15
Trailing 4 Quarters Revenue $401.1 Million 9/15
Trailing 4 Quarters Earnings $32.6 Million 7/15
Quarterly Earnings Growth 117% 3/15
Annual Earnings Growth 215% 1/15
Quarterly Revenue Growth 64% 2/15
Annual Revenue Growth 79% 2/15
Cash On Hand $330.1 Million 2/15
Short Term Debt $2.5 Million 6/15
Long Term Debt $508.5 Million 4/15

TransMedics Group, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare TransMedics Group, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 62.15 5/15
PS 5.06 9/15
PB 9.66 6/15
PC 6.15 12/15
Liabilities to Equity 2.74 2/15
ROA 0.04 4/15
ROE 0.16 5/15
Current Ratio 1.36 13/15
Quick Ratio 0.57 10/15
Long Term Debt to Equity 2.42 2/15
Debt to Equity 2.42 2/15
Burn Rate 19.69 1/15
Cash to Cap 0.16 3/15
CCR -9.81 15/15
EV to EBITDA 258.96 3/15
EV to Revenue 5.50 9/15

Company Details

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

CEO: Dr. Waleed H. Hassanein

Website: https://www.transmedics.com

Address: 200 Minuteman Rd Boston, MASSACHUSETTS

Exchange: NASDAQ Global Market

Industry: Medical Devices

TransMedics Group, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to TransMedics Group, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Insulet Corporation PODD $18.5 Billion
Masimo Corporation MASI $9.2 Billion
Penumbra, Inc. PEN $10.0 Billion
Orthofix Medical Inc. OFIX $685.6 Million
Inspire Medical Systems, Inc. INSP $5.3 Billion
InMode Ltd. INMD $1.4 Billion
ShockWave Medical, Inc. SWAV $12.6 Billion
Silk Road Medical, Inc SILK $1.1 Billion
TELA Bio, Inc. TELA $106.3 Million
Delcath Systems, Inc. DCTH $406.4 Million
Inari Medical, Inc. NARI $4.6 Billion
Pulmonx Corporation LUNG $265.4 Million
NeuroPace, Inc. NPCE $358.2 Million
CVRx, Inc. CVRX $412.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
TMDX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 108.8 Million $4.2 Million
Q2 2024 $ 114.3 Million $12.2 Million
Q1 2024 $ 96.9 Million $12.2 Million
Q4 2023 $ 81.2 Million $4.0 Million
Q3 2023 $ 66.4 Million -$25.4 Million
Q2 2023 $ 52.5 Million -$1.0 Million
Q1 2023 $ 41.6 Million -$2.6 Million
Q4 2022 $ 31.4 Million -$6.7 Million

View All

TMDX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $330.1 Million $785.6 Million $508.5 Million $209.9 Million
Q2 2024 $362.8 Million $758.6 Million $516.5 Million $189.9 Million
Q1 2024 $350.2 Million $723.8 Million $516.2 Million $159.5 Million
Q4 2023 $394.8 Million $706.0 Million $515.9 Million $137.2 Million
Q3 2023 $427.1 Million $689.2 Million $456.7 Million $126.5 Million
Q2 2023 $582.2 Million $690.4 Million $515.0 Million $145.2 Million
Q1 2023 $195.4 Million $287.1 Million $67.3 Million $192.6 Million
Q4 2022 $201.2 Million $277.1 Million $67.6 Million $187.4 Million

View All

TMDX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$41.3 Million -$48.2 Million -$32.7 Million
Q2 2024 $2.0 Million -$23.8 Million $12.5 Million
Q1 2024 -$47.6 Million -$44.2 Million -$44.6 Million
Q4 2023 -$33.5 Million -$41.8 Million -$32.3 Million
Q3 2023 $0 $0 $0
Q2 2023 $0 $0 $0
Q1 2023 -$9.6 Million -$927,000 -$5.6 Million
Q4 2022 -$6.8 Million -$2.8 Million -$3.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions